Pharma Bullish 6

Kestra Medical Surges 63% on Assure Growth and Strategic VA Expansion

Kestra Medical reported a 63% year-over-year revenue increase to $24.6 million in Q3 2026, driven by record prescriptions for its Assure wearable cardioverter defibrillator. The company significantly expanded its market access through a new U.S. Department of Veterans Affairs contract and improved Medicaid coverage in Florida.

· 3 min read · By Biotech Intelligence Brief Editorial
Share

Key Takeaways

  • Kestra Medical reported a 63% year-over-year revenue increase to $24.6 million in Q3 2026, driven by record prescriptions for its Assure wearable cardioverter defibrillator.
  • The company significantly expanded its market access through a new U.S.
  • Department of Veterans Affairs contract and improved Medicaid coverage in Florida.

Mentioned

Kestra Medical company KMTS Brian Webster person Vaseem Mahboob person Assure system product U.S. Department of Veterans Affairs organization FDA organization

Key Intelligence

Key Facts

  1. 1Revenue grew 63% year-over-year to $24.6 million
  2. 2Gross margin reached 52.6%, marking nine straight quarters of expansion
  3. 3Assure system prescriptions surpassed 5,400 for the quarter
  4. 4Cash and equivalents totaled $291 million as of January 31, 2026
  5. 5Secured placement on the VA Federal Supply Schedule for nationwide access
Market Outlook

Analysis

Kestra Medical’s Q3 2026 results signal a pivotal shift in the wearable cardioverter defibrillator (WCD) landscape. With revenue hitting $24.6 million, the company is proving that its Assure system can successfully challenge established incumbents. The 63% year-over-year growth isn’t just a fluke of a small base; it’s backed by a 58% surge in prescriptions, totaling over 5,400 for the quarter. This trajectory suggests that Kestra is effectively penetrating both new and existing accounts, leveraging a sales force that is rapidly scaling toward its 130-territory goal by the end of the fiscal year.

Beyond the top-line growth, the most impressive metric in this report is the gross margin expansion. Reaching 52.6%—a 900 basis point improvement over the previous year—marks the ninth consecutive quarter of sequential growth. This trend is a testament to Kestra’s operational maturing. CFO Vaseem Mahboob highlighted that this was driven by higher revenue per fit and improved efficiency in the revenue cycle. Specifically, the company’s in-network billing mix has climbed to the low 80% range, up significantly from 70% at the time of its IPO. This shift reduces administrative friction and accelerates the conversion of prescriptions into realized revenue.

With revenue hitting $24.6 million, the company is proving that its Assure system can successfully challenge established incumbents.

Strategic market access wins are poised to serve as the primary growth engines for the remainder of 2026. The addition of the Assure system to the U.S. Department of Veterans Affairs’ Federal Supply Schedule is a watershed moment. This grants Kestra streamlined access to the massive VA hospital network, a demographic that often has a high prevalence of the cardiac conditions the Assure system is designed to monitor. Simultaneously, the company’s success in securing managed Medicaid provider status in Florida—including agreements with two of the state's four largest plans—opens a significant new patient population. Florida’s large elderly and at-risk demographic makes it a critical geography for cardiac monitoring technologies.

What to Watch

However, the path to profitability remains capital-intensive. The GAAP net loss widened to $34.2 million, largely due to the aggressive expansion of the sales organization and nonrecurring professional fees. While the adjusted EBITDA loss of $21.2 million shows a similar widening, the company’s balance sheet remains robust. Following a successful equity offering in December, Kestra holds $291 million in cash. This war chest provides the necessary runway to fund the planned increase to 130 active sales territories without immediate pressure for further dilution, assuming the current burn rate remains managed.

Looking ahead, investors and industry analysts should focus on two key variables: the upcoming Medicare reimbursement update and the continued improvement of the conversion rate. The current conversion rate of 46% is a healthy step up from last year’s 43%, but there is still significant leakage between a prescription being written and a device being fitted and billed. If Kestra can push this rate toward the 50% mark while maintaining its current prescription growth, the path to break-even will accelerate. The company’s focus on high-volume geographies with robust payer coverage suggests a disciplined approach to scaling that favors quality of revenue over raw volume.

Timeline

Timeline

  1. Equity Offering

  2. Q3 Fiscal End

  3. Earnings Release

  4. Expansion Target

Cite This Page

"Kestra Medical Surges 63% on Assure Growth and Strategic VA Expansion." Biotech Intelligence Brief, March 18, 2026. https://getbiobrief.com/story/kestra-medical-kmts-q3-2026-earnings-analysis

Related Stories

Pharma

49-Year Species Rule Ends: Biotech’s Natural Drug Library Faces Extinction Risk

The U.S. Interior Department’s cancellation of automatic ESA protections for threatened species could accelerate biodiversity loss, directly threatening the natural sources of many pharmaceuticals. Bioprospecting and natural product R&D face heightened uncertainty as habitat destruction outpaces species discovery. The rule change adds regulatory complexity for biotech companies seeking access to rare organisms.

Pharma

Only 92 Deals: Big Pharma's TrumpRx Offering Covers Under 12% of Its 800+ Drug Stable

TrumpRx, the Trump administration's drug discount website, has secured voluntary pricing deals on only 92 brand-name drugs—less than 12% of the 800-plus products from 17 major pharmaceutical companies. High-cost therapies for inflammatory diseases, HIV, and cancer are largely excluded, raising doubts about industry's willingness to compromise on pricing without legislation.

Pharma

5,100 Suspected Cyclospora Cases Drive Demand for Rapid Diagnostics and New Therapies

The CDC's health alert on a cyclosporiasis outbreak with 5,100 suspected cases presents urgent needs in the biotech sector for rapid diagnostics, antiparasitic drug development, and food safety technologies. The parasite Cyclospora cayetanensis, with its long incubation period, challenges traditional detection methods, while treatment relies on a decades-old antibiotic. Innovators could capitalize on multiplex PCR panels and next-generation sequencing for outbreak tracking.

Pharma

Novartis, Roche Face 50% PBS Price Cut on MS Drugs as Briumvi Triggers Review

A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.

How we covered this story

Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled biotech-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.